[Secondary chemotherapy in advanced ovarian cancer--new drugs].
The results of secondary chemotherapy in advanced ovarian carcinoma are reviewed. After treatment with alkylants average rates of remission of 40 to 45% are achieved. The duration of remission is about 5 months. The response after treatment with platin is significantly lower. Furthermore, new drugs are summarized. A new class of agents is not identifiable. Advances are to be expected in platin derivates with lower nephrotoxicity rates.
D000477:Alkylating Agents / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D009279:Naphthacenes / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D009279:Naphthacenes; D002945:Cisplatin
Sekundäre Chemotherapie beim fortgeschrittenen Ovarialkarzinom--neue Medikamente.